In the final days of 2025, EU regulators issued a surprise mandate that reshapes the landscape for AI-driven medical devices. A new guidance requires the use of Real-World Evidence (RWE) for continuous, post-market validation of AI/ML algorithms, impacting all companies planning to enter or remain in the European market. This episode of MedTech Global Insights breaks down what this means for your 2026 submission strategy and beyond.

We explore the shift from a one-time approval to a dynamic lifecycle approach and what this signals for the future of global MedTech regulation. This change introduces significant new hurdles for manufacturers, demanding a proactive and integrated strategy for data collection and analysis long after a product has been launched.

A Specific Case: Imagine you are a startup like Cardio-AI. Your breakthrough AI product for heart failure prediction was ready for EU launch. Now, this last-minute RWE mandate has invalidated your clinical strategy, delaying market entry by a year and adding millions in unplanned costs. How do you recover?

Key Takeaways:

- What exactly is in the new EU guidance on RWE for AI devices?

- Why was this sudden change implemented without warning?

- How does this affect my existing CE mark or submission plans for 2026?

- Does my current clinical evidence strategy meet these new demands?

- What kind of post-market data infrastructure do I need to build now?

- Is my Notified Body prepared to audit against this new guidance?

- How will this EU shift influence FDA or other global regulations?

- What are the immediate steps to de-risk my product launch pipeline?

Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.